Cellipont Bioservices Names Brett Reynolds as New CFO
An experienced financial leader joins to support strategic growth and expansion goals.
Cellipont Bioservices, a leading cell therapy CDMO, has appointed Brett Reynolds as Chief Financial Officer (CFO), effective immediately. With over 25 years of financial leadership experience, primarily in the life sciences sector, Reynolds steps into the role following the retirement of Tim Heher.
Reynolds, a seasoned CFO with a proven track record in high-growth businesses, will oversee Cellipont’s financial strategy, IT operations, and support the company’s expansion plans. His expertise spans profitability enhancement, financial planning, M&A, and investor relations. “Brett’s experience makes him the ideal leader as we scale operations and innovate for our clients and their patients,” said Darren Head, CEO of Cellipont Bioservices. Reynolds expressed enthusiasm about contributing to Cellipont’s mission of advancing life-changing treatments.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion